Skip to main content
SpringerLink
Log in

Systemic Therapies for Patients with Liver Tumors: Prospects for the Future

  • Conference paper
Therapeutic Strategies in Primary and Metastatic Liver Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 100))

Abstract

Attempts to identify effective chemotherapy for patients with liver metastases represent a specific aspect of the more general search for meaningfully beneficial systemic chemotherapy of primary and metastatic tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Huberman MS (1983) Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Semin Oncol 10, 2: 238–248

    PubMed  CAS  Google Scholar 

  2. Kemeny N (1983) The systemic chemotherapy of hepatic metastases. Semin Oncol 10, 2: 148–158

    PubMed  CAS  Google Scholar 

  3. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, Steele G, Frei E III (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer 38: 3784–3792

    CAS  Google Scholar 

  4. Ensminger W, Dakhil S, Doan K, Cho K, Wheeler R, Pollard HM (1981) Clinical pharmacology of dichloromethotrexate in hepatic arterial infusions. Proc AACR 22: 271

    Google Scholar 

  5. Tester WJ, Donehower RC, Eddy JE, Myers CE, Ihde DC (1982) Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors. Cancer Chemother Pharmacol 8: 305–310

    Article  PubMed  CAS  Google Scholar 

  6. Bertino JR, Sawicki WL, Lindquist CA, Gupta VS (1977) Schedule dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37: 327–328

    PubMed  CAS  Google Scholar 

  7. Cadman E, Heimer R, Davis L (1979) Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 205: 1135–1137

    Article  PubMed  CAS  Google Scholar 

  8. Benz C, Cadman E (1981) Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res 41: 994–999

    PubMed  CAS  Google Scholar 

  9. Cadman E, Heimer R, Benz C (1981) The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256: 1695–1704

    PubMed  CAS  Google Scholar 

  10. Weinerman B, Schacter B, Schipper, Bowman D, Levitt M (1982) Sequential methotrexate and 5-FU in the treatment of colorectal cancer. Cancer Treat, Rep 66: 1553–1555

    CAS  Google Scholar 

  11. Solan A, Vogl SE, Kaplan BH, Berenzweig M, Richard J, Lanham R (1982) Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil. Med Pediatr Oncol 10: 145–149

    Article  PubMed  CAS  Google Scholar 

  12. Cantrell, Jr. JE, Brunet R, Lagard C, Schein PS, Smith FP (1982) Phase II study of sequential methotrexate-5-FU therapy in advanced measurable clorectal cancer. Cancer Treat Rep 66: 1563–1565

    PubMed  Google Scholar 

  13. Herrmann R, Manegold C, Rittinghausen R, Fritze D, Schettler G (1981) Sequential methotrexate (MTX) and 5-fluorouracil (FU) in colo-rectal adenocarcinoma. Results of a pilot study. Proc ASCO/AARC 22: 457

    Google Scholar 

  14. Drapkin R, Griffiths E, McAloon E, Paladine W, Sokol G, Lyman G (1981) Sequential methotrexate (MTX) and 5-fluorouracil (5-FU) in adenocarcinoma of the colon and rectum. Proc ASCO/AACR 22: 453

    Google Scholar 

  15. Mehrotra S, Rosenthal CJ, Gardner B (1982) Biochemical modulation of antineoplastic response in colorectal carcinoma: 5-fluorouracil (F), high dose methotrexate (M) with calcium leukovorin (L) rescue ( FML) in two sequences of administration. Proc ASCO 1: 100

    Google Scholar 

  16. Kemeny N, Michaelson R (1982) Phase II trial of low dose methotrexate and sequential 5-fluorouracil in the treatment of metastatic colorectal carcinoma. Proc ASCO 1: 95

    Google Scholar 

  17. Mahajan SL, Ajani JA, Kanojia MD, Bedikian AY (1983) Comparison of two schedules of sequential high-dose methotrexate (MTX) and 5-fluorouracil (5-FU) for metastatic colorectal carcinoma. Proc ASCO 2: 122

    Google Scholar 

  18. Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SW, Espinoza EG, Bodey GP (1985) Sequential conventional dose methotrexate (MTX) and 5-fluorouracil (5-FU) in the primary therapy of metastatic colorectal carcinoma. Am J Clin Oncol 8 (1): 69

    Article  PubMed  CAS  Google Scholar 

  19. Hansen R, Ritch P, Anderson T (1983) Sequential methotrexate (MTX), 5-fluorouracil (5-FU), and leukovorin (LCV) in colorectal cancer. Proc ASCO 2: 117

    Google Scholar 

  20. Ullman B, Lee M, Martin DW, Santi DV (1978) Cytotoxicity of 5-fluoro-2’-deoxyuridine: requirement for reduced folate cofactors and antagonism of methotrexate. Proc Nat Acad Sci USA 75: 980–983

    Article  PubMed  CAS  Google Scholar 

  21. Evans RM, Laskin JD, Hakala M (1981) Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3283–3295

    Google Scholar 

  22. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R, Mathe G (1982) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil (5-FU) combined with high dose folinic acid (FA). Proc Am Soc Clin Oncol 1: 33

    Google Scholar 

  23. Bruckner HW, Ohnuma T, Hart R, Jaffrey I, Spiegelman M, Ambinder E, Storch JA, Wilfinger C, Goldberg J, Biller H, Holland JF (1982) Leucovorin (LV) potentiation of 5-fluorouracil (FU) efficiency and potency. Proc Am Assoc Cancer Res 23: 111

    Google Scholar 

  24. Bruckner HW, Storch JA, Holland JF (1981) Leucovorin increases the toxicity of 5-fluorouracil: phase I clinical pharmacological trials. Proc Assoc Clin Res 22: 192

    Google Scholar 

  25. Bruckner HW, Roboz J, Spigelman M, Ambinder E, Hart R, Holland JF (1983) An efficient leucovorin and 5-fluorouracil sequence: dosage escalation and pharmacological monitoring. Proc Am Assoc Cancer Res 23: 138

    Google Scholar 

  26. Byrne P, Smith F, Treat J, Bowers MW, McVie G, Hunink TB, Schein P (1983) 5-fluorouracil and higher dose for folinic acid treatment of colorectal carcinoma patients. Proc ASCO 474: 121

    Google Scholar 

  27. Cunningham J, Bukowski R, Budd T, Hewlett J, Purvis J (1983) Folinic acid (FA) combined with 5-flourouracil (5-FU): phase I-II clinical trial. Proc ASCO 167: 42

    Google Scholar 

  28. Schabel FM, Trader MW, Laster WR, Corbott TH, Griswold DP (1979) Cis-dichlorodiammine platinum (II): combination chemotherapy and cross resistance studies with tumors of mice. Cancer Treat Rep 63: 1459–73

    PubMed  CAS  Google Scholar 

  29. Kovach JS, Moertel CG, Schutt AJ, O’Connell MJ (1983) Phase II study of cis-diammine dichloroplatinum (NSC-1 119 875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 57: 357–358

    Google Scholar 

  30. Einhorn L, Williams SD, Loehrer RI (1984) Combination chemotherapy with platinum (P) plus 5-FU in metastatic colorectal carcinoma. Proc ASCO 520: 133

    Google Scholar 

  31. Schilsky RL, Brown H, Monaghan G, Muscato J, Perry MC (1983) Phase I trial of cytosine arabinoside (Ara-C) and cis-platin (DDP) in patients with advanced cancer. Proc ASCO 2: 20

    Google Scholar 

  32. Bergerat J-P, Drewinko B, Corry P, Barlogie B, Ho DH (1981) Synergistic lethal effect of cisdichlorodiammineplatinum and 1-µ-D-arabino-furanosylcytosin. Cancer Res 41: 25–30

    PubMed  CAS  Google Scholar 

  33. Grant S, Cadman E (1982) Modulation of 1-µ-D-arabinofuranosylcytosin metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment. Cancer Res 42. 3550–3556

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Landow Building, Room 4A04, Bethesda, MD, 20892, USA

    M. A. Friedman

Authors
  1. M. A. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chirurgische Klinik, Klinikum der Universität Heidelberg, Im Neuenheimer Feld 110, 6900, Heidelberg 1, Germany

    Christian Herfarth , Peter Schlag  & Peter Hohenberger ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Friedman, M.A. (1986). Systemic Therapies for Patients with Liver Tumors: Prospects for the Future. In: Herfarth, C., Schlag, P., Hohenberger, P. (eds) Therapeutic Strategies in Primary and Metastatic Liver Cancer. Recent Results in Cancer Research, vol 100. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82635-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-82635-1_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-82637-5

  • Online ISBN: 978-3-642-82635-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation